tenofovir disoproxil

Tenofovir Disoproxil (GS 4331) is a nucleotide reverse transcriptase inhibitor to treat HIV and chronic Hepatitis B.

Tenofovir disoproxil aspartate, a nucleotide reverse transcriptase inhibitor, is used potentially for the treatment of HBV infection.

Tenofovir Disoproxil Fumarate (GS-1278 Disoproxil Fumarate) is a pro-drug, fumaric acid salt form of tenofovir, a nucleoside reverse transcriptase inhibitor analog of adenosine. Tenofovir disoproxil fumarate is prescribed to treat HIV and chronic hepatitis B virus (HBV) in adults.

9-Propenyladenine (9-PA) is a mutagenic impurity in tenofovir disoproxil fumarate (TDF).

(Z)-9-Propenyladenine is a mutagenic impurity in tenofovir disoproxil fumarate.

Tenofovir disoproxil fumarate is a nucleotide reverse transcriptase inhibitor employed in the treatment of HIV and chronic hepatitis B.

Tenofovir diphosphate is an inhibitor of HIV reverse transcriptase (Kis = 0.022 and 1.55 μM for RNA and DNA, respectively) and hepatitis B virus (HBV) polymerase (Ki = 0.18 μM). It is selective for these enzymes over DNA polymerase α and β, as well as mitochondrial DNA polymerase γ (Kis = 5.2, 81.7, and 59.5 μM, respectively). Tenofovir diphosphate is formed intracellularly through phosphorylation of the prodrugs tenofovir and tenofovir disoproxil by nucleotide kinases. Increased levels of tenofovir diphosphate in isolated peripheral blood mononuclear cells (PBMCs) correlate with a decrease in the risk of simian HIV (SHIV) acquisition in a macaque model of rectal SHIV transmission.